Bone Marrow CD34+ Stem/Progenitor Cells, Frozen | StemExpress

Bone Marrow CD34+ Stem/Progenitor Cells, Frozen

In stock
Category: Research Products
Select SKU Size / Day Price
BM34000.5C 0.5 million/vial $810 USD
BM34001C 1 million/vial $1,231 USD
BM34002C 2 million/vial $1,898 USD
Questions about shipping? See Shipping Info
Questions? Contact Sales:
Contact Us
Product Description

CD34 is a glycosylated transmembrane protein and represents a well-established marker for human hematopoietic stem and progenitor cells in peripheral blood, bone marrow, and cord blood. CD34+ cells are self-renewing, multipotent stem cells that give rise to all blood cells of the immune system through a process called hematopoiesis. As hematopoietic stem cells progress through hematopoiesis they generate the myeloid (monocytes, macrophages, granulocytes, megakaryocytes, dendritic cells, erythrocytes) and lymphoid (T cells, B cells, NK cells) lineages. The highly specialized cells that arise from hematopoietic stem cells work collaboratively in defending the body against infection and disease.

Bone marrow mononuclear cells (MNCs) are separated from whole bone marrow by a density gradient centrifugation protocol. CD34+ cells are positively selected using immunomagnetic anti-CD34 (clone QBEND10) microbeads from bone marrow mononuclear cells. Isolated primary cells are characterized by flow cytometry before cryopreservation to ensure a highly pure and viable cell population.

Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols.

More Information
Species Human
Disease State Healthy
Cell and Tissue Source Bone Marrow
Product Type Primary Cells
Cell Type Stem/Progenitor Cells
Donor Attributes HIV-, HepB-, HepC-
Purity ≥90% by Flow Cytometry
Viability ≥70% by Flow Cytometry
Format Frozen
Contains StemSpan™ and 10% DMSO
Anticoagulant Na-Heparin

Product Information Sheet

Certificate of Analysis

Material Safety Data Sheet


  • 1 Eksioglu et al. (2017) Novel Therapeutic Approach to Improve Hematopoiesis in Low Risk MDS by Targeting MDSCs with the
    Fc-engineered CD33 Antibody BI 836858
    . Leukemia 1-9. doi:10.1038/leu.2017.21.
  • 2 Hudak et al. (2014) Glycocalyx Engineering Reveals a Siglec-Based Mechanism for NK Cell Immunoevasion. Nat Chem Biol 10: 69-75. doi:10.1038/nchembio.1388. Abstract
  • 3 Modarai et al. (2018) Efficient Delivery and Nuclear Uptake Is Not Sufficient to Detect Gene Editing in CD34+ Cells Directed by a Ribonucleoprotein Complex. Mol Ther Nucl Acids 11: 116-129. Article
  • 4 Cheng et al. (2019) S100A9-Induced Overexpression of PD-1/PD-L1 Contributes to Ineffective Hematopoiesis in Myelodysplastic Syndromes. Leukemia. Article
  • 5 Lo et al. (2020) Potent In Vitro Activity of β-D-4ʹ-Chloromethyl-2ʹ-Deoxy-2ʹ-Fluorocytidine Against Nipah Virus. Antivir Res Abstract


Figure 1. Representative flow analysis of CD34+ cells enriched from bone marrow mononuclear cells prior to cryopreservation.

Hi, have questions?

A StemExpress Expert is happy to help!

Call 530.303.3828 or Contact Us